o
|
Preliminary
Proxy Statement
|
o
|
Confidential,
for Use of The Commission Only (as permitted by Rule
14a-6(e)(2))
|
o
|
Definitive
Proxy Statement
|
o
|
Definitive
Additional Materials
|
x
|
Soliciting
Material Pursuant to
§240.14a-12
|
x
|
No
fee required
|
o
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
(2)
|
Aggregate
number of securities to which transaction
applies:
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is
calculated and state how it was
determined):
|
(4)
|
Proposed
maximum aggregate value of
transaction:
|
(5)
|
Total
fee paid:
|
o
|
Fee
paid previously with preliminary
materials.
|
o
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its
filing.
|
(1)
|
Amount
Previously Paid:
|
(2)
|
Form,
Schedule or Registration Statement
No.:
|
(3)
|
Filing
Party:
|
(4)
|
Date
Filed:
|
December 20, 2006 |
· |
While
the Company’s results in 2006 declined from 2005, a substantial portion of
the revenues realized in 2004 and 2005, directly or indirectly stemmed
from lawsuits initiated in 1993 and 1999, long
before Mr. Nano joined the Company.
For example, the Materna case was initiated in 1993 and reached a
final,
non-appealable judgment in April 2004, when we received our award
of
several million dollars. The case involving Laboratory Corporation
of
America Holdings (“LabCorp”) was initiated in 1999 when LabCorp was sued
for infringing the Company’s homocysteine patent. The decisions of two
courts, the District Court in December 2001 and the Court of Appeals
for
the Federal Circuit in August 2004, both upheld the validity of our
patent, and the August 2004 decision was essential to our ability
to
pursue other infringers. The result was dramatically increased
revenues in fiscal year 2005.
|
· |
The
Nano Group claims in its proxy material that Mr. Nano was largely
responsible for strong stock price appreciation during 2004. We believe
that the real reason for the appreciation in our stock price was
from the
substantial revenue and cash the Company realized from the judgments
rendered in our favor in connection with lawsuits commenced prior
to Mr.
Nano’s hiring.
|
· |
Over
the past calendar year, we have added a significant number of new
technologies to our development portfolio that are available for
licensing.
Some of these exciting new technologies will be highlighted in our
annual
report, which you will receive shortly.
|
· |
We
have added service offerings that build on our core expertise in
technology transfer, intellectual property and licensing.
During
fiscal 2006, we launched our IP Valuation and Market Assessment services,
as well as a Technology Sourcing business. These are important parts
of
our strategy as they complement our core
business.
|
· |
The
fruits of our labor will take time to surface as the nature of our
business is such that there is an 18 to 36-month period from the
point of
identifying a new technology to the point of realizing any revenue,
a fact
that we have consistently reported to you on our quarterly conference
calls and in press releases. The infrastructure referred to above
is one
of the most important components of our strategy and one that we
believe
can assure sustainable sources of revenue for the
Company.
|
Richard E. Carver | Maria Maccecchini, Ph.D. |
George W. Dunbar, Jr. | Charles J. Philippin |
D.J. Freed, Ph.D. | John. M. Sabin |